Loading
BS
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Stock: price and insider trades · China
阳光诺和
Beijing Sun-Novo Pharmaceutical Research Co., Ltd.: what insiders have been doing
Every trade that managers of Beijing Sun-Novo Pharmaceutical Research Co., Ltd. disclose to SSE / SZSE (CSRC) is tracked on this page. The company sits in the Health Care sector. Over the twelve months to 18 October 2026, 2 filings were filed, from 2 insiders.
All open-market trades in the period are sales: 2 sales worth €190k, by 2 insiders, with no purchase on record. Biggest ticket of the year: €115k, sold by 袁瑜 and made public on 4 September 2026.
A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
For context, the typical company on the same exchange (median of 514 companies) published 2 filings over the same period, against 2 filings here. Since 2024, the database holds no purchases and 3 sales by insiders of the company.
Elsewhere in the same sector, our signals recently picked up insider purchases at MAIA Biotechnology, Inc. and Cooper Companies, Inc. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.
Insider Decl.
3
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€5M
3 ops. · all time
Who traded when
BuySale孟广鹏1 sale
袁瑜1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 13,276 of 24,166 companies
48.7
score / 100
Value36
Quality61
FCF yld0.7%
Earn yld3.0%
EV/EBITDA26.7x
ROE4.5%
Gross mgn54%
Net mgn17%
Debt/EBITDA2.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CN¥64.32
Analyst consensus
Income statement
RevenueCN¥1.2B
Gross profitCN¥661.4M54% margin
EBITDACN¥277.3M23% margin
Net incomeCN¥203.9M4.7% margin
Valuation
PER (trailing)139.8x
P/Book5.8x
Beta0.10
Balance sheet & cash
Market capCN¥7.2B
Total debtCN¥613.7M
Free Cash FlowCN¥50.8M
Debt / Equity56%
Profitability & ownership
ROE4.5%
ROA0.6%
% insiders37.0%
% institutions7.9%
Last declaration on 4 September 2026
About Beijing Sun-Novo Pharmaceutical Research Co., Ltd.
阳光诺和 is a company operating in the healthcare and pharmaceutical sector, listed on the Shanghai Stock Exchange. It focuses on the development and commercialization of innovative pharmaceutical products.
